Preparation of isotope-labeled ketoglutaric acid and method for hyperpolarization by reversible exchange signal amplification (SABRE)

By providing isotope labeled α-ketoglutarate compounds with improved performance, the problem of low T1 relaxation rate in HP-13C-MRI is solved, and efficient cancer diagnosis and monitoring is achieved, meeting the needs of performance improvement and preparation methods. .

CN118946535AInactive Publication Date: 2024-11-12THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026889.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-26
Filing Date
2023-01-26
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In hyperpolarized carbon-13 nuclear magnetic resonance imaging (HP-13C-MRI), the performance of existing isotope-labeled α-ketoglutarate compounds is insufficient, especially the low T1 relaxation rate, which makes it difficult to meet the improvement of performance and preparation methods. The need for restricting the diagnosis and monitoring of diseases such as cancer.

Method used

It is provided an isotope-labeled alpha-ketoglutaric acid compound, specifically a compound of formula (I), which comprises a hyperpolarized compound having improved properties and a pharmaceutically acceptable salt thereof, by specific synthetic methods and hyperpolarization. technology, which improves the T1 relaxation rate of the compound and is used for cancer diagnosis and monitoring.

Benefits of technology

It improves the performance of HP-13C-MRI, enhances the T1 relaxation rate, improves the permeability and diagnostic efficacy of compounds, and is suitable for the diagnosis and monitoring of diseases such as cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946535A_ABST
    Figure CN118946535A_ABST
Patent Text Reader

Abstract

Compounds of Formula (I), pharmaceutically acceptable salts thereof, and processes for their preparation are disclosed, # imgabs0 wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed are isotopic mixtures of the compounds of formula (I) and pharmaceutical compositions comprising the hyperpolarized compounds of formula (I). Also disclosed are methods of diagnosing or monitoring a patient suffering from cancer comprising administering a pharmaceutical composition comprising an effective amount of a hyperpolarized ketoglutaric acid compound or a pharmaceutically acceptable salt thereof and measuring hyperpolarization of a compound of interest in a patient. Further disclosed is a process for preparing a hyperpolarized ketoglutaric acid compound for use in the above process.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] U.S. federally funded research or development

[0002] This invention was made with U.S. Government support. The U.S. Government has certain rights in this invention.

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 303,190, filed on January 26, 2022, which is incorporated herein by reference in its entirety. Background Art

[0005] α-Ketoglutarate (α-KG) is a key metabolite and signaling molecule in cancer cells, but the low permeability of α-KG limits the study of α-KG-mediated effects in vivo. Cell-permeable mono- and diester α-KG derivatives have been synthesized for in vivo use, but many of these derivatives are not suitable for use in hyperpolarized carbon-13 nuclear magnetic resonance imaging (HP-13NMR). 13 C-MRI). Certain isotope-labeled α-ketoglutarate compounds and their use as hyperpolarized imaging agents, therapeutic agents or diagnostic agents and methods for their preparation have been disclosed. See, for example, WO 2021 / 146572A1; AbuSalim et al., “Simple Esterification of [1- 13 C]-Alpha-Ketoglutarate Enhances Membrane Permeability and Allows for Noninvasive Tracing of Glutamate and Glutamine Production,” ACSChem. Biol. 2021, 16, 2144-2150 (Sept. 23, 2021).

[0006] However, for the HP- 13 There remains an unmet need for isotope-labeled α-KG compounds with improved properties in C-MRI (e.g., increased T1 relaxation rate of the carbonyl group) and methods of preparing such compounds, methods of preparing hyperpolarized isotope-labeled α-KG compounds, and methods of detecting and / or monitoring various diseases in patients by using these compounds. Summary of the invention

[0007] The present invention provides a method for producing a 13Isotope-labeled α-KG compounds with improved performance in C-MRI (e.g., increased T1 relaxation rate, i.e., the time required for the z component of M to reach about 63% of (1-1 / e) or its maximum value (Mo)). More specifically, the present invention provides compounds of formula (I):

[0008]

[0009] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0010] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0011] or a pharmaceutically acceptable salt thereof.

[0012] The present invention also provides a composition comprising an isotopic mixture of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0013]

[0014] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0015] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein at least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd are deuterium.

[0016] The present invention further provides a hyperpolarized compound of formula (I), a hyperpolarized composition comprising an isotopic mixture of the compound of formula (I), a pharmaceutical composition comprising an effective amount of a hyperpolarized compound of formula I, and a pharmaceutical composition comprising a hyperpolarized isotopic mixture of the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0017] The present invention further provides a method of diagnosing or monitoring a patient having or suspected of having cancer, the method comprising administering a hyperpolarized ketoglutarate compound, e.g., a hyperpolarized compound of formula (I), a hyperpolarized isotope mixture of a compound of formula (I), or a hyperpolarized compound of formula (IV):

[0018]

[0019] or a pharmaceutical composition comprising a hyperpolarized compound of formula (I), a hyperpolarized isotope mixture of a compound of formula (I) or a hyperpolarized compound of formula (IV), and a pharmaceutical composition comprising a hyperpolarized compound of formula (I), a hyperpolarized isotope mixture of a compound of formula (I) or a hyperpolarized compound of formula (IV) 13 C-MRI to diagnose or monitor patients.

[0020] The present invention also provides processes for preparing compounds of formula (I) and processes for preparing hyperpolarized variants and isotopic mixtures thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 A synthetic scheme for preparing mono-3-deuterated ketoglutarate according to aspects of the present invention is shown.

[0022] Figure 2 The NMR results obtained for compounds in one aspect of the present invention are shown. The top scan shows [1- 13 C,5- 12 Single-sweep hyperpolarization (HP) of sodium ketoglutarate 13 C. The bottom scan shows the 13 Single-scan thermal polarization of sodium acetate 13 C signal.

[0023] Figures 3A-3H Provides [1- 13 C,5- 12 C; d4] Results of the SABRE-SHEATH hyperpolarization process of α-ketoglutarate. Figure 3A It shows [1- 13 C,5- 12 C; d4] Schematic diagram of the SABRE-SHEATH hyperpolarization process of α-ketoglutarate and the related polarization transfer pathway. Figure 3B Provides hyperpolarization [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C NMR spectroscopy. Figure 3C Provides 5mM [1- 13 C,5- 12 C; d4] Temperature variation of representative stacking of α-ketoglutarate 13 C NMR spectroscopy. Figure 3D Provides thermally polarized pure [1- 13 C]Acetic acid 13 C NMR spectroscopy. Figure 3E Provides a diagram showing the T =0.42μT [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13Plot of the build up and decay of the C polarization (ie, integrating over all bound and free resonances). Figure 3F The corresponding results of the magnetic field of the Earth and the clinically relevant 1.4T magnetic field of the benchtop spectrometer are provided. 13 C-1Plot of the T1 relaxation curve. Figure 3G Provides a diagram showing [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13 Plot of C polarization as a function of temperature. Figure 3H Provides a diagram showing [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13 Plot of C polarization as a function of magnetic transfer field.

[0024] Figures 4A-4G Results from the SABRE-SHEATH hyperpolarization method for naturally abundant disodium α-ketoglutarate are presented. Figure 4A is a schematic diagram showing the SABRE-SHEATH hyperpolarization method of α-ketoglutarate disodium and the associated polarization transfer pathway. Figure 4B Provided is a representative sample of a 5.6 mM solution of naturally abundant disodium α-ketoglutarate obtained by SABRE-SHEATH in CD3OD at +10 °C 13 C NMR spectroscopy. Figure 4C Provides thermally polarized pure [1- 13 C]Acetic acid 13 C NMR spectroscopy. Figure 4D Provides a diagram showing the T =0.42μT and T T = Total in disodium α-ketoglutarate at +10°C 13 Plot of the superposition and attenuation of the C polarization (ie, integrating over all bound and free resonances). Figure 4E The total (bound + free) values ​​of α-ketoglutarate disodium at the Earth's magnetic field and the clinically relevant 1.4 T magnetic field of a benchtop spectrometer are provided. 13 Plot of C polarization attenuation. Figure 4F Provided is a diagram showing the natural abundance of α-ketoglutarate disodium 13 C-1 Total 13 Plot of C polarization as a function of temperature. Figure 4G Provided is a diagram showing the natural abundance of α-ketoglutarate disodium 13 C-1 Total 13 Plot of C polarization as a function of magnetic transfer field. DETAILED DESCRIPTION

[0025] According to one aspect, the present invention provides a compound of formula (I):

[0026]

[0027] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0028] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0029] or a pharmaceutically acceptable salt thereof.

[0030] For example, the compound of formula (I) may be one of the following:

[0031] (i) wherein one of Xa and Xb is deuterium and the other is hydrogen, and both Xc and Xd are hydrogen, as shown in formula (Ia):

[0032]

[0033] or a pharmaceutically acceptable salt thereof,

[0034] (ii) wherein one of Xc and Xd is deuterium and the other is hydrogen, and both Xa and Xb are hydrogen, as shown in formula (Ib):

[0035]

[0036] or a pharmaceutically acceptable salt thereof,

[0037] (iii) wherein one of Xa and Xb is deuterium and the other is hydrogen, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (Ic):

[0038]

[0039] or a pharmaceutically acceptable salt thereof,

[0040] (iv) wherein both Xa and Xb are deuterium, and both Xc and Xd are hydrogen, as shown in formula (Id):

[0041]

[0042] or a pharmaceutically acceptable salt thereof,

[0043] (v) wherein both Xa and Xb are hydrogen, and both Xc and Xd are deuterium, as shown in formula (Ie):

[0044]

[0045] or a pharmaceutically acceptable salt thereof,

[0046] (vi) wherein both Xa and Xb are deuterium, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (If):

[0047]

[0048] or a pharmaceutically acceptable salt thereof,

[0049] (vii) wherein both Xc and Xd are deuterium, and one of Xa and Xb is deuterium and the other is hydrogen, as shown in formula (Ig):

[0050]

[0051] or a pharmaceutically acceptable salt thereof, or

[0052] (viii) wherein Xa, Xb, Xc and Xd are deuterium, as shown in formula (Ih):

[0053]

[0054] or a pharmaceutically acceptable salt thereof.

[0055] In any aspect of the compounds of formula (I) described herein (e.g., formula (Ia)-(Ih)), each R1 can be independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl. In some embodiments, each R1 is independently selected from C1-C6 alkyl, for example, each R1 can be methyl, ethyl, propyl (e.g., isopropyl or n-propyl), butyl (e.g., isobutyl, n-butyl, tert-butyl or sec-butyl), pentyl or hexyl. In some embodiments, each R1 is independently selected from hydrogen, deuterium and a cation. In embodiments where R1 is a cation, one of ordinary skill in the art will readily appreciate that the compound of Formula (I) (e.g., Formula (Ia)-(Ih)) is a salt (e.g., a pharmaceutically acceptable salt) in which the negative charge on the oxygen is balanced by the cation.

[0056] In another aspect, the present invention provides a composition comprising an isotopic mixture of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0057]

[0058] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0059] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein Xa+

[0060] At least 25% of the sum of deuterium atoms and hydrogen atoms defined by Xb+Xc+Xd is deuterium. In other words, the present invention provides an isotopic mixture of compounds of formula (I), wherein, on average, at least one of Xa+Xb+Xc+Xd is deuterium. When referring to a composition comprising an isotopic mixture, it is understood that, except for the isotopic labeling, each compound in the composition comprising the isotopic mixture is structurally identical, that is, each R1 is defined consistently. All other aspects of the compounds of formula (I) (e.g., formulas (Ia)-(Ih)) in the composition comprising an isotopic mixture are as described herein.

[0061] In some embodiments of the isotopic mixture of the compound of formula (I), at least 25% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium. For example, in the compound of formula (I), Xa can be hydrogen or deuterium, Xb can be hydrogen or deuterium, Xc can be hydrogen or deuterium, and Xd can be hydrogen or deuterium, and the isotopic mixture of the compound of formula (I) can have any combination of labels so that on average at least one of Xa, Xb, Xc and Xd is deuterium. In some embodiments of the isotopic mixture of the compound of formula (I), at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium. In other words, the isotopic mixture of the compound of formula (I) can have any combination of labels so that on average at least two of Xa, Xb, Xc and Xd are deuterium. In other embodiments of the isotopic mixture of the compound of formula (I), at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium. In other words, the isotopic mixture of the compound of formula (I) can have any combination of labels so that on average at least three of Xa, Xb, Xc and Xd are deuterium. In certain embodiments of the isotopic mixture of the compound of formula (I), at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium. In other words, the isotopic mixture of the compound of formula (I) can have any combination of labels so that on average all or almost all of Xa, Xb, Xc and Xd are deuterium. Thus, a composition comprising an isotopic mixture of compounds of Formula (I) can have 25% to 100% (e.g., 25% to 95%, 25% to 75%, 25% to 50%, 50% to 100%, 50% to 95%, 50% to 75%, 75% to 100%, or 75% to 95%) of the sum of the deuterium atoms and hydrogen atoms defined by Xa, Xb, Xc, and Xd being deuterium.

[0062] In some embodiments of the isotopic mixture of formula (I) compound, at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium. For example, in formula (I) compound, Xa can be hydrogen or deuterium and Xb can be hydrogen or deuterium, and the isotopic mixture of formula (I) compound can have any combination of labels so that on average at least one of Xa and Xb is deuterium. In some embodiments of the isotopic mixture of formula (I) compound, at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xa and Xb is deuterium. In other embodiments of the isotopic mixture of formula (I) compound, at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium. In other words, the isotopic mixture of formula (I) compound can have any combination of labels so that on average all or almost all of Xa and Xb are deuterium. Thus, a composition comprising an isotopic mixture of compounds of Formula (I) can have 50% to 100% (e.g., 50% to 95%, 50% to 75%, 75% to 100%, or 75% to 95%) of the sum of the deuterium atoms and hydrogen atoms defined by Xa and Xb being deuterium.

[0063] Optionally or additionally, in some embodiments of the isotopic mixture of formula (I) compound, at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium. For example, in formula (I) compound, Xc can be hydrogen or deuterium and Xd can be hydrogen or deuterium, and the isotopic mixture of formula (I) compound can have any combination of labels so that on average at least one of Xc and Xd is deuterium. In some embodiments of the isotopic mixture of formula (I) compound, at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xc and Xd is deuterium. In other embodiments of the isotopic mixture of formula (I) compound, at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium. In other words, the isotopic mixture of formula (I) compound can have any combination of labels so that on average all or almost all of Xc and Xd are deuterium. Thus, a composition comprising an isotopic mixture of compounds of formula (I) can have 50% to 100% (e.g., 50% to 95%, 50% to 75%, 75% to 100%, or 75% to 95%) of the sum of the deuterium atoms and hydrogen atoms defined by Xc and Xd being deuterium.

[0064] The present invention further provides a pharmaceutical composition comprising a hyperpolarized compound of formula (I) (e.g., an effective amount of a hyperpolarized compound of formula (I)) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. All aspects of the compound of formula (I) and its hyperpolarization are as described herein.

[0065] The present invention further provides a pharmaceutical composition comprising a hyperpolarized composition and a pharmaceutically acceptable carrier, wherein the hyperpolarized composition comprises an isotopic mixture of a compound of formula (I) (e.g., an effective amount of an isotopic mixture of a compound of formula (I)) or a pharmaceutically acceptable salt thereof. As used herein, the phrase "hyperpolarized composition comprising an isotopic mixture of a compound of formula (I)" refers to a composition comprising an isotopic mixture of a compound of formula (I), wherein one or more of the isotopes are hyperpolarized. In other words, the hyperpolarized composition comprising an isotopic mixture of a compound of formula (I) comprises a hyperpolarized isotopic mixture of a compound of formula (I). All aspects of the compound of formula (I), isotopic mixtures, and hyperpolarization thereof are as described herein.

[0066] The present invention further provides a method for diagnosing or monitoring a patient suffering from or suspected of suffering from cancer, the method comprising administering a hyperpolarized ketoglutarate compound or pharmaceutical composition as described above and 13 C-MRI diagnosis or monitoring of patients. For example, a hyperpolarized compound of formula (I) (e.g., an effective amount of a hyperpolarized compound of formula (I)) or a hyperpolarized composition comprising an isotopic mixture of a compound of formula (I) (e.g., an effective amount of an isotopic mixture of a compound of formula (I)), or a pharmaceutical composition comprising a hyperpolarized composition, can be used in a method for diagnosing or monitoring a patient suffering from cancer or suspected of having cancer. For example, in some embodiments, the present invention provides a hyperpolarized compound of formula (I) (e.g., an effective amount of a hyperpolarized compound of formula (I)) or a hyperpolarized composition comprising an isotopic mixture of a compound of formula (I) (e.g., an effective amount of an isotopic mixture of a compound of formula (I)), or a pharmaceutical composition comprising a hyperpolarized composition in a method for diagnosing or monitoring a patient suffering from cancer or suspected of having cancer, the method comprising: 13 C-MRI diagnoses or monitors patients. In some embodiments, the method or use comprises identifying one or more mutations that cause cancer. In certain embodiments, the method or use identifies IDH1 mutations that cause cancer. In other words, the method or use can be used to identify whether a patient has a tumor, e.g., an IDH1 mutation.

[0067] The present invention further provides a method for preparing a compound of formula (I) (e.g., formula (Ia)-(Ih)) or a pharmaceutically acceptable salt thereof, as described herein, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising:

[0068] (i) reacting a compound of formula (II) with deuterium oxide in an organic solvent under alkaline conditions to obtain a compound of formula (III):

[0069]

[0070] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, and wherein Bn is benzyl; and

[0071] (ii) reacting the compound of formula (III) with DCl and D2O or HCl and H2O to obtain a compound of formula (I) (e.g., formula (Ia)-(Ih)) or a pharmaceutically acceptable salt thereof. All other aspects of the compound of formula (I) are as described herein. In some embodiments, each R1 is hydrogen and the method comprises reacting the compound of formula (III) with HCl and H2O. In some embodiments, each R1 is deuterium and the method comprises reacting the compound of formula (III) with DCl and D2O. In some embodiments, each R1 is a cation and the method further comprises (iii) reacting the compound of formula (I) with a base.

[0072] The present invention further provides a method for preparing an isotopic mixture of a compound of formula (I), as described herein, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising:

[0073] (i) reacting a compound of formula (II) with a deuterium oxide in an organic solvent under alkaline conditions to obtain an isotopic mixture of a compound of formula (III):

[0074]

[0075] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein at least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium; and

[0076] (ii) reacting an isotopic mixture of a compound of formula (III) with DCl and D2O or HCl and H2O to obtain an isotopic mixture of a compound of formula (I) or a pharmaceutically acceptable salt thereof. All other aspects of the isotopic mixture of a compound of formula (I) are as described herein. In some embodiments, each R1 and the method comprises reacting a compound of formula (III) with HCl and H2O. In some embodiments, each R1 is deuterium and the method comprises reacting a compound of formula (III) with DCl and D2O. In some embodiments, each R1 is a cation and the method further comprises (iii) reacting a compound of formula (I) with a base.

[0077] The present invention further provides a method for preparing a compound of formula (I) (e.g., formula (Ia)-(Ih)) or a pharmaceutically acceptable salt thereof, as described herein, wherein each R1 is independently selected from hydrogen and a cation, the method comprising:

[0078] (i) reacting a compound of formula (II) with deuterium oxide in an organic solvent under alkaline conditions to obtain a compound of formula (III):

[0079]

[0080] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, and wherein Bn is benzyl; and

[0081] (ii) reacting the compound of formula (III) with HCl and H2O to obtain a compound of formula (I) (e.g., formula (Ia)-(Ih)) or a pharmaceutically acceptable salt thereof. All other aspects of the compound of formula (I) are as described herein. In some embodiments, each R1 is a cation and the method further comprises (iii) reacting the compound of formula (I) with a base.

[0082] The present invention further provides a method for preparing an isotopic mixture of a compound of formula (I), as described herein, wherein each R1 is independently selected from hydrogen and a cation, the method comprising:

[0083] (i) reacting a compound of formula (II) with deuterium oxide in an organic solvent under alkaline conditions to obtain a compound of formula (III):

[0084]

[0085] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein Xa+

[0086] At least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xb+Xc+Xd is deuterium; and

[0087] (ii) reacting the isotopic mixture of the compound of formula (III) with HCl and H2O to obtain the isotopic mixture of the compound of formula (I) or a pharmaceutically acceptable salt thereof. All other aspects of the isotopic mixture of the compound of formula (I) are as described herein. In some embodiments, each R1 is a cation and the method further comprises (iii) reacting the compound of formula (I) with a base.

[0088] The present invention further provides a method for preparing a compound of formula (D):

[0089]

[0090] include:

[0091] (i) epoxidizing a compound of formula (A) to obtain an epoxide compound of formula (B):

[0092]

[0093] (ii) deuterating the compound of formula (B) to obtain a compound of formula (C):

[0094] as well as

[0095] (iii) oxidizing the compound of formula (C) in an alkaline solution to obtain a compound of formula (D). In some embodiments, the compound of formula (B) is deuterated by reacting with NaBD4 in a solution of D2O and lithium bromide. Alternatively or additionally, in some embodiments, the alkaline solution in (iii) comprises 4-(dimethylamino)pyridine and sodium bicarbonate.

[0096] The present invention further provides a method for preparing a compound of formula (L):

[0097]

[0098] wherein each R1 is independently H or alkyl, the method comprising:

[0099] (i) reacting a compound of formula (E) with tert-butyldimethylsilyl chloride (TBSCl) bonded to imidazole, followed by catechol borane and water to obtain a compound of formula (F):

[0100]

[0101] (ii) by reacting a compound of formula (F) with a 12 The bromomethyl ester of C ester carbonyl is reacted in a basic medium to esterify the compound of formula (F) to obtain the compound of formula (G), wherein R1 is H or alkyl:

[0102]

[0103] (iii) reacting a compound of formula (G) with tetrabutylammonium fluoride to obtain a compound of formula (H):

[0104]

[0105] (iv) epoxidizing a compound of formula (H) to obtain a compound of formula (J):

[0106]

[0107] (v) deuterating the compound of formula (J) by reacting the compound of formula (J) with deuterated lithium / deuterated copper to obtain a compound of formula (K):

[0108] as well as

[0109] (vi) oxidizing the compound of formula (K) to obtain the compound of formula (L). In some embodiments, the epoxidation is carried out by reaction with an alkali metal tungstate and hydrogen peroxide. Alternatively or additionally, in some embodiments, the compound of formula (B) is deuterated by reaction with NaBD4 in D2O containing LiBr.

[0110] The present invention further provides a method for preparing a compound of formula (L):

[0111]

[0112] Wherein R1 is H or alkyl, the method comprises:

[0113] (i) reacting a compound of formula (M) with trimethylsilyl trifluoromethanesulfonate and palladium (0) to obtain a compound of formula (N):

[0114]

[0115] (ii) epoxidizing a compound of formula (N) to obtain a compound of formula (P):

[0116]

[0117] (iii) reacting a compound of formula (P) with sodium deuterated borohydride in D2O with lithium bromide to obtain a compound of formula (Q):

[0118] as well as

[0119] (iv) oxidizing a compound of formula (Q) in an alkaline solution to obtain a compound of formula (L). The compound of formula (Q) can be oxidized to obtain ketoglutaric acid by any suitable method. In some embodiments, the compound of formula (Q) is oxidized to form ketoglutaric acid by Dess-Martin oxidation. Alternatively or additionally, in some embodiments, the epoxidation of the compound of formula (N) is carried out by reacting with a rare earth metal-biphenyldiol-Ph3-As=O complex. Alternatively or additionally, in some embodiments, the compound of formula (B) is deuterated by reacting with NaBD4 in D2O containing LiBr. Alternatively or additionally, in some embodiments, the alkaline solution in (iv) contains 4-(dimethylamino)pyridine and sodium bicarbonate.

[0120] exist Figure 1 An exemplary epoxidation method for synthesizing mono-3-deuterated ketoglutarate according to aspects of the invention is provided in .

[0121] The present invention further provides a method for preparing a hyperpolarized ketoglutarate compound, comprising:

[0122] (i) providing a SABRE polarization transfer precatalyst;

[0123] (ii) combining the SABRE polarization transfer precatalyst with a ketoglutarate compound, parahydrogen, and optionally a co-ligand in a solvent to form a mixture comprising an active SABRE catalyst; and

[0124] (iii) hyperpolarizing the mixture by exposing the mixture comprising the active SABRE catalyst to a magnetic field or radio frequency excitation to transfer the polarization from the parahydrogen to the ketoglutarate compound to form the hyperpolarized ketoglutarate compound.

[0125] The ketoglutarate compound can be any suitable ketoglutarate compound regardless of isotopic content. For example, the ketoglutarate compound can be deuterated, non-deuterated, or a mixture of isotopes thereof. Typically, the ketoglutarate compound is 13 C-labeled, and more specifically, labeled 13 C is at the C1 position. In some embodiments, the ketoglutarate compound is a compound of formula (I) or (IV):

[0126]

[0127] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0128] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0129] or a pharmaceutically acceptable salt thereof.

[0130] Each R1 can be independently selected from hydrogen, deuterium, cation, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl) C1-C6 alkyl, (heterocycloalkyl) C1-C6 alkyl, (heteroaryl) C1-C6 alkyl and (aryl) C1-C6 alkyl. In some embodiments, each R1 is independently selected from C1-C6 alkyl, for example, each R1 can be methyl, ethyl, propyl (for example, isopropyl or n-propyl), butyl (for example, isobutyl, n-butyl, tert-butyl or sec-butyl), pentyl or hexyl. In some embodiments, each R1 is independently selected from hydrogen, deuterium and cation. In the embodiment where R1 is a cation, it should be readily understood by those of ordinary skill in the art that the compound of formula (I) (for example, formula (Ia)-(Ih)) is a salt (for example, a pharmaceutically acceptable salt) in which the negative charge on oxygen is balanced by a cation. In certain embodiments, each R1 is independently a cation or C1-C6 alkyl.

[0131] In some embodiments, the ketoglutarate compound is an isotopic mixture of compounds of Formula (I) described herein.

[0132] The method for preparing a hyperpolarized ketoglutaric acid compound includes providing a SABRE polarization transfer precatalyst. The SABRE (Signal Amplification by Reversible Exchange) polarization transfer precatalyst can be any suitable SABRE polarization transfer precatalyst, many of which are known in the art. In some embodiments, the SABRE polarization transfer precatalyst comprises a d-block element such as Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au and / or Hg. In certain embodiments, the SABRE polarization transfer precatalyst comprises an element of Group 9 of the periodic table, i.e., Co, Rh, Ir or Mt. In a preferred embodiment, the SABRE polarization transfer precatalyst comprises Ir or Co. For example, the SABRE polarization transfer precatalyst can be [Ir(COD)(IMes)(Cl)].

[0133] In some embodiments, the SABRE polarization transfer precatalyst may comprise one or more ligands, for example, a phosphine ligand, a carbene ligand, an imidazole ligand, and / or a pincer ligand. Alternatively, the SABRE polarization transfer precatalyst may comprise a tridentate chelating ligand. In some embodiments, the SABRE polarization transfer precatalyst comprises a phosphine ligand. Typically, the phosphine ligand of the precatalyst is electron-rich and sterically demanding, and gives very high polarization transfer to pyridine protons. Examples of phosphine ligands include, but are not limited to, the following:

[0134]

[0135] In some embodiments, the SABRE polarization transfer precatalyst comprises a carbene ligand. Typically, carbene ligands such as N-heterocyclic carbene (NHC) ligands can also provide very high polarization levels and can even provide higher polarization than phosphine ligands due to the increased steric volume and electron donation capacity of NHC. Another advantage is that they provide faster substrate dissociation. Examples of NHCs include, but are not limited to, the following:

[0136]

[0137]

[0138] Wherein IMes is 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene.

[0139] Alternatives to IMes include IMes variants with para-, meta- and / or ortho-substituted IMes. Exemplary alternatives include, but are not limited to, the following para-substituted IMes:

[0140]

[0141]

[0142] Ortho-substituted IMes:

[0143]

[0144] Meta-substituted IMes:

[0145] And other IMes:

[0146]

[0147]

[0148]

[0149] as well as

[0150] In some embodiments, the SABRE polarization transfer precatalyst comprises a pincer chelating ligand. Exemplary pincer chelating ligands include, but are not limited to, the pincer chelating ligands shown in the following SABRE polarization transfer precatalysts:

[0151]

[0152] These SABRE polarization transfer precatalysts may also be suitable for the methods described herein.

[0153] In some embodiments, the SABRE catalyst can be prepared using a water-soluble SABRE polarization transfer precatalyst. The water-soluble SABRE polarization transfer precatalyst can be prepared by any suitable method. For example, a water-soluble SABRE polarization transfer precatalyst can be prepared by adding a polar group to an NHC ligand, including a choline moiety or including an alkoxy (e.g., pegylated) group. Exemplary water-soluble SABRE polarization transfer precatalysts include, but are not limited to, the following:

[0154]

[0155] The SABRE polarization transfer precatalyst may also be a heterogeneous catalyst suitable for in vivo applications. For example, the SABRE polarization transfer precatalyst may be an iridium catalyst that is immobilized on a solid support, such as,

[0156] Polymer microbeads:

[0157]

[0158] Core-shell nanoparticles (or nano-SABRE catalysts):

[0159]

[0160] Polymer Comb:

[0161]

[0162] This is schematically shown below:

[0163] And silica-bonded catalysts:

[0164]

[0165] The active SABRE catalyst can be prepared by any suitable method. Typically, the active SABRE catalyst combines a SABRE polarization transfer precatalyst with a ketoglutaric acid compound, secondary hydrogen and an optional co-ligand in a solvent to form a mixture comprising an active SABRE catalyst to prepare. In some embodiments, the active SABRE catalyst combines a SABRE polarization transfer precatalyst with a ketoglutaric acid compound, secondary hydrogen and a co-ligand in a solvent to form a mixture comprising an active SABRE catalyst to prepare. The co-ligand, when included in the preparation of the active SABRE catalyst, can be combined with the SABRE polarization transfer precatalyst in any order and by any suitable method. For example, when the co-ligand is included in the preparation of the active SABRE catalyst, the co-ligand can first be provided to interact with the transfer precatalyst to promote the formation of the active SABRE catalyst. Alternatively, the co-ligand, when included in the preparation of the active SABRE catalyst, can be added together with the ketoglutaric acid compound to promote the formation of the active SABRE catalyst. In some embodiments, the co-ligand, ketoglutaric acid compound and parahydrogen are substantially combined with the SABRE polarization transfer precatalyst in a solvent simultaneously to promote the formation of an active SABRE catalyst. In other embodiments, the ketoglutaric acid compound is first provided to interact with the transfer precatalyst to promote the formation of an active SABRE catalyst. In some embodiments, the co-ligand and ketoglutaric acid compound are combined with the SABRE polarization transfer precatalyst in a solvent, and parahydrogen is added to (e.g., bubbled through) the resulting mixture. In other embodiments, the ketoglutaric acid compound is combined with the SABRE polarization transfer precatalyst in a solvent, and parahydrogen is added to (e.g., bubbled through) the resulting mixture.

[0166] In some embodiments, the active SABRE catalyst is prepared by combining a SABRE polarization transfer precatalyst with a co-ligand other than a ketoglutaric acid compound and parahydrogen. Any suitable co-ligand can be used. For example, the co-ligand can be a compound containing a sulfoxide group. Examples of compounds containing a sulfoxide group can be selected from DMSO, phenylmethyl sulfoxide, chloromethylphenyl sulfoxide, diphenyl sulfoxide, dibenzoyl sulfoxide, and dibutyl sulfoxide.

[0167] The method can be carried out in any suitable solvent. In some embodiments, the solvent includes water (e.g., deionized water) and optionally one or more water-miscible organic solvents. In other embodiments, the solvent includes one or more organic solvents. Examples of organic solvents that can be used in the method include alcohols, such as propylene alcohol, isopropyl alcohol, ethanol, 1-propanol, methanol, 1-hexanol, etc.; ketones, such as acetone, diacetone alcohol, methyl ethyl ketone, etc.; esters, such as ethyl formate, propyl formate, ethyl acetate, methyl acetate, methyl lactate, butyl lactate, ethyl lactate, etc.; ethers (including sulfoxides), such as dimethyl sulfoxide (DMSO), tetrahydrofuran, dioxane, diethylene glycol dimethyl ether, etc.; amides, such as N,N-dimethylformamide, dimethylimidazolidinone, N-methylpyrrolidone, etc.; polyols and their derivatives, such as ethylene glycol, glycerol, diethylene glycol, diethylene glycol monomethyl ether, etc.; and nitrogen-containing organic compounds, such as acetonitrile, amylamine, isopropylamine, imidazole, dimethylamine, etc. In some embodiments, the solvent is water, that is, there is no organic solvent. The solvent can be a deuterated solvent or a non-deuterated solvent. In some embodiments, the solvent is a deuterated solvent. In other embodiments, the solvent is a non-deuterated solvent.

[0168] Parahydrogen can be combined with the SABRE polarization transfer precatalyst by any suitable method. For example, parahydrogen can be bubbled through a mixture comprising the SABRE polarization transfer precatalyst, parahydrogen can be added as a gas blanket to a mixture comprising the SABRE polarization transfer precatalyst, or a mixture comprising the SABRE polarization transfer precatalyst can be placed under high pressure parahydrogen. In some embodiments, parahydrogen is bubbled through a mixture comprising the SABRE polarization transfer precatalyst. For example, the active SABRE catalyst can be prepared by adding parahydrogen to the precatalyst in the presence of an excess of substrate. In some embodiments, the SABRE catalyst is prepared as follows:

[0169]

[0170] [Ir(COD)(IMes)(Cl)],

[0171] Wherein IMes is 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene.

[0172] Therefore, the active SABRE (signal amplification by reversible exchange) catalyst comprises at least a d-block element, for example, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au and / or Hg, parahydrogen and ketoglutaric acid compounds. In certain embodiments, the active SABRE catalyst comprises an element of Group 9 of the periodic table, i.e., Co, Rh, Ir or Mt. In a preferred embodiment, the active SABRE catalyst comprises Ir or Co. In some embodiments, the active SABRE catalyst comprises a ligand present on a SABRE polarization transfer precatalyst. For example, the active SABRE catalyst may include a phosphine ligand, a carbene ligand, an imidazole ligand, and / or a pincer ligand.

[0173] In some embodiments, the active SABRE catalyst includes a co-ligand. Any suitable co-ligand can be used. For example, the co-ligand can be a compound containing a sulfoxide group. Examples of compounds containing a sulfoxide group can be selected from DMSO, phenylmethyl sulfoxide, chloromethylphenyl sulfoxide, diphenyl sulfoxide, dibenzoyl sulfoxide and dibutyl sulfoxide.

[0174] Thus, in some embodiments, the active SABRE catalyst comprises at least a d-block element (e.g., Ir or Co), parahydrogen, a ketoglutarate compound, and a co-ligand. In other embodiments, the active SABRE catalyst comprises at least a d-block element (e.g., Ir or Co), parahydrogen, a ketoglutarate compound, a co-ligand, and one or more ligands.

[0175] In some embodiments, the active SABRE catalyst comprises a salt of a compound of formula (I) that undergoes polarization transfer to obtain a hyperpolarized compound. Examples of active SABRE catalysts are:

[0176]

[0177] wherein R is a cation described herein (e.g., Na + ).

[0178] The method for preparing hyperpolarized ketoglutarate described herein comprises hyperpolarizing the mixture by exposing the mixture containing the active SABRE catalyst to a magnetic field or radio frequency excitation to transfer polarization from the secondary hydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound. Initially, the hyperpolarized ketoglutarate compound is complexed with the hyperpolarized SABRE catalyst; however, it will be understood by those of ordinary skill in the art that the hyperpolarized ketoglutarate compound can be replaced by other ketoglutarate compound molecules so that the process can be repeated and free hyperpolarized ketoglutarate compounds are produced.

[0179] The transfer of polarization from the parahydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound can occur under any suitable magnetic field or radio frequency excitation. For example, the transfer of polarization from the parahydrogen to the carbon atom of the ketoglutarate compound can occur in a magnetic field below the earth's magnetic field. The appropriate level of magnetic field or radio frequency excitation required to transfer polarization from the parahydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound should be clear to those of ordinary skill in the art.

[0180] In some embodiments, the method comprises replenishing parahydrogen in the mixture during the process of hyperpolarizing the mixture comprising an active SABRE catalyst by exposing the mixture to a magnetic field or radio frequency excitation to transfer polarization from parahydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound. In other words, in some embodiments, the method comprises bubbling parahydrogen through the mixture comprising an active SABRE catalyst during the process of hyperpolarizing the mixture comprising an active SABRE catalyst by exposing the mixture to a magnetic field or radio frequency excitation to transfer polarization from parahydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound.

[0181] In some embodiments, the hyperpolarized ketoglutarate compound has formula (HP-I) or (HP-IV):

[0182]

[0183] The arrows in formula (HP-I) and formula (HP-IV) represent hyperpolarization,

[0184] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0185] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0186] or a pharmaceutically acceptable salt thereof.

[0187] In the present application, the term "alkyl" refers to a saturated hydrocarbon group having a specific number of carbon atoms, typically 1 to 6. Examples of alkyl groups include methyl, ethyl, propyl (e.g., isopropyl or n-propyl), butyl (e.g., isobutyl, n-butyl, tert-butyl or sec-butyl), pentyl or hexyl.

[0188] In the present application, the term "cycloalkyl" refers to a saturated hydrocarbon ring group having a specific number of carbon atoms, typically 3 to about 7 carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and bridged or caged saturated ring groups, such as norbornane or adamantane.

[0189] In the present application, the term "cycloalkyl" refers to a saturated hydrocarbon ring group having a specific number of carbon atoms, typically 3 to about 7 carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and bridged or caged saturated ring groups, such as norbornane or adamantane.

[0190] The term "aryl" refers to a stable monocyclic or polycyclic substituted or unsubstituted aromatic ring having 5 to 60 ring carbon atoms, for example, phenyl, tolyl, xylyl, naphthyl, phenanthrenyl and anthracenyl.

[0191] The term "heteroaryl" refers to a stable monocyclic aromatic ring having the specified number of ring atoms, containing 1 to 3 or in some aspects 1 to 2 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, or to a stable bicyclic or tricyclic ring system containing at least one 5- to 7-membered aromatic ring containing 1 to 3 or in some aspects 1 to 2 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Monocyclic heteroaryls typically have 5 to 7 ring atoms, and in some aspects, bicyclic heteroaryls are 9- to 10-membered heteroaryls, i.e., groups containing 9 or 10 ring atoms, in which one 5- to 7-membered aromatic ring is fused to a second aromatic or non-aromatic ring. When the total number of S and O atoms in the heteroaryl exceeds 1, these heteroatoms are not adjacent to each other. It is preferred that the total number of S and O atoms in the heteroaryl does not exceed 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle does not exceed 1. Heteroaryl groups include, but are not limited to, oxazolyl, piperazinyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thienyl, triazolyl, benzoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, isothiazolyl, and isoxazolyl.

[0192] The term "heterocyclyl" refers to a saturated or unsaturated cyclic group having the specified number of ring atoms, which contains 1 to about 3 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Examples of heterocyclyl include piperazinyl and thiazolyl.

[0193] The term "heterocycloalkyl" refers to a saturated cyclic group having the specified number of ring atoms containing 1 to about 3 heteroatoms selected from N, O and S, the remainder of the ring atoms being carbon. Examples of heterocycloalkyl include tetrahydrofuranyl and pyrrolidinyl.

[0194] The term "pharmaceutical composition" refers to a composition comprising at least one active agent, such as a compound of formula (I) or a salt, and at least one other substance (such as a carrier, i.e., a diluent, an excipient, or a vehicle), with which the active compound is administered. A "pharmaceutically acceptable carrier" refers to a substance, such as an excipient, a diluent, or a vehicle, that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes acceptable carriers for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable carrier" includes one and more than one such carrier.

[0195] The term "patient" refers to a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition (e.g., a disease or disorder) or diagnostic treatment. In some embodiments, the patient is a human patient.

[0196] The term "treatment" or "treating" refers to providing an active compound to a patient in an amount sufficient to measurably reduce any symptoms of cancer, slow cancer progression, or cause cancer regression. In certain embodiments, cancer treatment can be initiated before a patient develops symptoms of the disease.

[0197] Formula (I) compound can contain one or more asymmetric elements such as stereocenter, stereoaxis, etc., such as asymmetric carbon atoms, so the compound can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can also be mixtures of diastereomers. For compounds with asymmetric centers, all optical isomers and mixtures thereof in pure form are encompassed. In these cases, single enantiomers, i.e. optically active forms can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by splitting racemates. The splitting of racemates can also be accomplished, for example, by conventional methods, such as crystallization in the presence of a splitting agent, or using, for example, the chromatography of a chiral HPLC column. All forms are contemplated herein, regardless of the method for obtaining them.

[0198] "Pharmaceutically acceptable salts" include derivatives of disclosed compounds, wherein the parent compound is modified by preparing inorganic and organic, nontoxic acid or base addition salts of the parent compound. The salt of the compound can be synthesized by a parent compound containing an alkaline or acidic part by conventional chemical methods. Typically, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of a suitable base (e.g., hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg or K), or reacting the free base form of these compounds with a stoichiometric amount of a suitable acid. Such reactions are typically carried out in water or an organic solvent or in a mixture of the two. Typically, non-aqueous media are used, such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile, where feasible. The salt of the compounds of the present invention further includes solvates of compounds and compound salts.

[0199] Examples of pharmaceutically acceptable salts include, but are not limited to, basic residues such as inorganic or organic acid salts of amines; acidic residues such as alkali metal or organic salts of carboxylic acids; etc. Pharmaceutically acceptable salts include conventional non-toxic salts and quaternary ammonium salts of the parent compound, such as those formed from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include salts derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; and salts prepared from organic acids, such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, methanesulfonic acid, esylicacid, besylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, HOOC-(CH2)n-COOH (wherein n is 0-4), and the like. Lists of other suitable salts can be found, for example, in G, Steffen Paulekuhn, et al., Journal of Medicinal Chemistry 2007, 50, 6665 and Handbook of Pharmaceutically Acceptable Salts: Properties, Selection and Use, P. Heinrich Stahl and Camille G. Wermuth Editors, Wiley-VCH, 2002. The composition may further include at least one pharmaceutically acceptable excipient. As used herein, pharmaceutically acceptable excipients refer to inactive pharmaceutical ingredients ("API") substances, such as disintegrants, binders, fillers and lubricants used to formulate drug products. Each of these substances is generally safe for human administration according to established government standards, including standards promulgated by the U.S. Food and Drug Administration ("FDA").

[0200] As used herein, the term "cation" refers to any positively charged ion capable of balancing the negative charge on a compound of formula (I). Typically, such cations are incorporated into salts (e.g., pharmaceutically acceptable salts) of a compound of formula (I) by reacting the free acid form of these compounds with a stoichiometric amount of an appropriate base (e.g., hydroxide, carbonate, bicarbonate, etc., of Na, Ca, Mg, or K).

[0201] As used herein, the disintegrant refers to one or more of agar, alginate, calcium carbonate, carboxymethyl cellulose, cellulose, clay, colloidal silicon dioxide, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, gum, magnesium aluminum silicate, methyl cellulose, polacrilin potassium, sodium alginate, low-substituted hydroxypropyl cellulose and cross-linked polyvinyl pyrrolidone, dioxypropyl cellulose, sodium starch glycolate and starch, but is not limited thereto.

[0202] The binder as used herein refers to one or more of microcrystalline cellulose, hydroxymethyl cellulose, and hydroxypropyl cellulose, but is not limited thereto.

[0203] Fillers as used herein refer to one or more of calcium carbonate, calcium phosphate, calcium hydrogen phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, dextrin derivatives, dextrin, glucose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, sorbitol, starch, sucrose, sugar and xylitol, but are not limited thereto.

[0204] The lubricant as used herein refers to one or more of agar, calcium stearate, ethyl oleate, ethyl laurate, glycerin, palmitostearin, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, ethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearate, sorbitol, stearic acid, talc and zinc stearate, but is not limited thereto.

[0205] Compositions according to the present invention can be applied to patients by various paths.The example of application path includes but is not limited to parenteral administration, for example, intravenous, intradermal, subcutaneous, oral, intranasal (for example, inhalation), transdermal (for example, topical), transmucosal and rectal administration.In embodiments, compositions are formulated into pharmaceutical compositions suitable for intravenous, subcutaneous, intramuscular, oral, intranasal or topical administration to people according to conventional procedures.Usually, the composition for intravenous administration is a solution in a sterile isotonic aqueous buffer.

[0206] According to any embodiment, the composition according to the present invention can be orally administered to a subject in need thereof. Preparations suitable for oral administration can be composed of: (a) liquid solutions, such as effective amounts of compounds dissolved in diluents (e.g., water, saline or orange juice), and including additives such as cyclodextrin or polyethylene glycol (e.g., PEG400); (b) capsules, sachets, tablets, lozenges and troche, each containing a predetermined amount of active ingredients that are solid or granules; (c) powders; (d) suspensions in suitable liquids; and (e) suitable emulsions and gels. Liquid preparations can include diluents such as water and alcohols, for example, ethanol, benzyl alcohol and polyvinyl alcohol, with or without the addition of pharmaceutically acceptable surfactants, suspending agents or emulsifiers. Capsule forms can be common hard-shell gelatin types or soft-shell gelatin types containing, for example, surfactants, lubricants and inert fillers (e.g., lactose, sucrose, calcium phosphate and corn starch). Tablet forms may include lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, gum arabic, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid and one or more of other excipients, colorants, diluents, buffers, disintegrants, wetting agents, preservatives, flavoring agents and pharmacologically compatible carriers. Lozenge forms may contain the active ingredient in a flavoring agent (usually sucrose and gum arabic or tragacanth), and pastilles contain the active ingredient in an inert matrix (e.g., gelatin and glycerin) or sucrose and gum arabic, and emulsions, gels, etc. contain such carriers known in the art in addition to the active ingredient.

[0207] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may contain suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The compositions according to the invention can be administered in a pharmaceutical carrier in a physiologically acceptable diluent, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, alcohols (e.g. ethanol, isopropanol or hexadecyl alcohol, glycols (e.g. propylene glycol or polyethylene glycol), glycerol ketals (e.g. 2,2-dimethyl-1,3-dioxolane-4-methanol), ethers (e.g. polyethylene glycol 400), oils, fatty acids, fatty acid esters or fatty acid glycerides, or acetylated fatty acid glycerides, with or without the addition of pharmaceutically acceptable surfactants (e.g. soaps or detergents), suspending agents (e.g. pectin, carbomer, methylcellulose, hydroxypropylmethylcellulose or carboxymethylcellulose), or emulsifiers and other pharmaceutical adjuvants.

[0208] The oil that can be used for parenteral preparations includes petroleum, animal oil, vegetable oil or synthetic oil. The specific example of oil includes peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, vaseline and mineral oil. Suitable fatty acids for parenteral preparations include oleic acid, stearic acid and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for parenteral preparations include fatty alkali metals, ammonium and triethanolamine salts, and suitable detergents include (a) cationic detergents, such as dimethyl dialkyl ammonium halides and alkyl pyridinium halides, (b) anionic detergents, such as alkyl, aryl and olefin sulfonates, alkyl, olefins, ethers and monoglyceride sulfates and sulfosuccinates, (c) nonionic detergents, such as fatty amine oxides, fatty acid alkanolamides and polyoxyethylene-polypropylene copolymers, (d) amphoteric detergents, such as alkyl-β-aminopropionic acid esters, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

[0209] Parenteral preparations usually contain about 0.5% by weight to about 25% by weight of the composition according to the present invention in the solution. Suitable preservatives and buffers can be used in these preparations. In order to minimize or eliminate the irritation of the injection site, this composition can contain one or more nonionic surfactants, which have a hydrophilic-lipophilic balance (HLB) of about 12 to about 17. The amount of the surfactant in this preparation ranges from about 5% by weight to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate, and ethylene oxide and the high molecular weight adducts of the hydrophobic base formed by the condensation of propylene oxide and propylene glycol. Parenteral preparations can be present in sealed containers (such as ampoules and vials) of unit doses or multiple doses, and can be stored under freeze drying (lyophilization) conditions, only needing to add a sterile liquid carrier immediately before use, such as water for injection.

[0210] The composition according to the present invention can be prepared into an injectable preparation. The requirements of injectable compositions for effective drug carriers are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, JB Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986).

[0211] The composition according to the present invention can be applied in an effective amount. "Effective amount" means an amount sufficient to bring substantial benefits to the patient. The effective amount can vary according to the biological effect required by the patient, the condition to be treated, and / or the specific characteristics and individuality of the composition according to the present invention. In this regard, according to the type of the desired biological effect or disease to be treated, the composition of any suitable dose can be applied to the patient (e.g., mankind). The various general factors considered when determining an "effective amount" are known to those skilled in the art and are described in, for example, in Gilman et al., eds., Goodman And Gilman's:The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Co., Easton, Pa., 1990, each of which is incorporated herein by reference. The dosage of the composition according to the present invention desirably includes about 0.1 mg per kilogram (kg) of patient body weight (mg / kg) to about 400 mg / kg (e.g., about 0.75 mg / kg, about 5 mg / kg, about 30 mg / kg, about 75 mg / kg, about 100 mg / kg, about 200 mg / kg, or about 300 mg / kg). In another embodiment, the dosage of the composition according to the present invention includes about 0.5 mg / kg to about 300 mg / kg (e.g., about 0.75 mg / kg, about 5 mg / kg, about 50 mg / kg, about 100 mg / kg, or about 200 mg / kg), about 10 mg / kg to about 200 mg / kg (e.g., about 25 mg / kg, about 75 mg / kg, or about 150 mg / kg), or about 50 mg / kg to about 100 mg / kg (e.g., about 60 mg / kg, about 70 mg / kg, or about 90 mg / kg).

[0212] In one aspect, dosages of compositions according to the invention desirably include from about 0.1 millimole (mmol) per kilogram (kg) of patient body weight (mmol / kg) to about 10 mmol / kg (e.g., about 0.1 mmol / kg, about 0.5 mmol / kg, about 1 mmol / kg, about 1.5 mmol / kg, about 2 mmol / kg / kg, about 2.5 mmol / kg / kg, about 3 mmol / kg, about 4 mmol / kg, about 5 mmol / kg, about 6 mmol / kg, about 7 mmol / kg, about 8 mmol / kg, about 9 mmol / kg, or about 10 mmol / kg).

[0213] The method for diagnosing or monitoring includes providing a dose of an activating agent to the patient. The dosage level of about 0.1 millimole (mmol) per kilogram (kg) of patient body weight (mmol / kg) to about 10mmol / kg of each activating agent can be used for the method for diagnosing or monitoring (for example, about 0.1mmol / kg, about 0.5mmol / kg, about 1mmol / kg, about 1.5mmol / kg, about 2mmol / kg / kg, about 2.5mmol / kg / kg, about 3mmol / kg, about 4mmol / kg, about 5mmol / kg, about 6mmol / kg, about 7mmol / kg, about 8mmol / kg, about 9mmol / kg or about 10mmol / kg).

[0214] The dosage level of about 0.1 mg to about 140 mg per kg of body weight per day of each activating agent can be used for the method of diagnosis or monitoring (about 0.5 mg to about 7 g per patient per day). The amount of the compound that can be combined with a carrier material to produce a single dosage form will vary according to the patient and a specific mode of administration for treatment. The dosage unit form will generally contain about 1 mg to about 500 mg of each active compound. In certain embodiments, 25 mg to 500 mg or 25 mg to 200 mg of activating agent is provided to the patient every day. The dosage frequency can also vary according to the specific diagnosis or monitoring method used by the compound used. However, for many diagnosis or monitoring methods, 4 times a day or less dosage regimens and once or twice a day dosage regimens can be used in certain embodiments.

[0215] Aspects of the Disclosure

[0216] The aspects of the invention described herein (including embodiments) may be beneficial alone or in combination with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure numbered 1-47 are provided below. As will be clear to those skilled in the art when reading this disclosure, each of the separately numbered aspects may be used or combined with any of the preceding or following separately numbered aspects. This is intended to provide support for the combination of all such aspects and is not limited to the combinations of the aspects explicitly provided below:

[0217] (1) Compound of formula (I):

[0218]

[0219] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0220] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0221] or a pharmaceutically acceptable salt thereof.

[0222] (2) The compound according to aspect 1, wherein one of Xa and Xb is deuterium and the other is hydrogen, and both Xc and Xd are hydrogen, as shown in formula (Ia):

[0223]

[0224] or a pharmaceutically acceptable salt thereof.

[0225] (3) The compound according to aspect 1, wherein one of Xc and Xd is deuterium and the other is hydrogen, and both Xa and Xb are hydrogen, as shown in formula (Ib):

[0226]

[0227] or a pharmaceutically acceptable salt thereof.

[0228] (4) The compound according to aspect 1, wherein one of Xa and Xb is deuterium and the other is hydrogen, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (Ic):

[0229]

[0230] or a pharmaceutically acceptable salt thereof.

[0231] (5) The compound according to aspect 1, wherein both Xa and Xb are deuterium, and both Xc and Xd are hydrogen, as shown in formula (Id):

[0232]

[0233] or a pharmaceutically acceptable salt thereof.

[0234] (6) The compound according to aspect 1, wherein both Xa and Xb are hydrogen, and both Xc and Xd are deuterium, as shown in formula (Ie):

[0235]

[0236] or a pharmaceutically acceptable salt thereof.

[0237] (7) The compound according to aspect 1, wherein both Xa and Xb are deuterium, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (If):

[0238]

[0239] or a pharmaceutically acceptable salt thereof.

[0240] (8) The compound according to aspect 1, wherein both Xc and Xd are deuterium, and one of Xa and Xb is deuterium and the other is hydrogen, as shown in formula (Ig):

[0241]

[0242] or a pharmaceutically acceptable salt thereof.

[0243] (9) The compound according to aspect 1, wherein Xa, Xb, Xc and Xd are deuterium, as shown in formula (Ih):

[0244]

[0245] or a pharmaceutically acceptable salt thereof.

[0246] (10) A compound according to any one of aspects 1-9, wherein each R1 is independently selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C1-C6 alkyl, (heterocycloalkyl)C1-C6 alkyl, (heteroaryl)C1-C6 alkyl and (aryl)C1-C6 alkyl.

[0247] (11) A compound according to any one of aspects 1 to 9, wherein each R1 is independently selected from C1-C6 alkyl.

[0248] (12) The compound according to any one of aspects 1-9, wherein each R1 is hydrogen.

[0249] (13) The compound according to any one of aspects 1-9, wherein each R1 is deuterium.

[0250] (14) The compound according to any one of aspects 1 to 9, wherein each R1 is a cation.

[0251] (15) A composition comprising an isotopic mixture of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0252]

[0253] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0254] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein at least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd are deuterium.

[0255] (16) The composition according to aspect 15, wherein at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

[0256] (17) The composition according to aspect 15, wherein at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

[0257] (18) The composition according to aspect 15, wherein at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

[0258] (19) The composition according to any one of aspects 15-18, wherein at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

[0259] (20) The composition according to any one of aspects 15-18, wherein at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

[0260] (21) The composition according to any one of aspects 15-18, wherein at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

[0261] (22) The composition according to any one of aspects 15-21, wherein at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

[0262] (23) The composition according to any one of aspects 15-21, wherein at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

[0263] (24) The composition according to any one of aspects 15-21, wherein at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

[0264] (25) A composition according to any one of aspects 15-24, wherein each R1 is independently selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C1-C6 alkyl, (heterocycloalkyl)C1-C6 alkyl, (heteroaryl)C1-C6 alkyl and (aryl)C1-C6 alkyl.

[0265] (26) The composition according to any one of aspects 15-24, wherein each R1 is independently a C1-C6 alkyl group.

[0266] (27) The composition according to any one of aspects 15-24, wherein each R1 is hydrogen.

[0267] (28) The composition according to any one of aspects 15-24, wherein each R1 is deuterium.

[0268] (29) The composition according to any one of aspects 15-24, wherein each R1 is a cation.

[0269] (30) A pharmaceutical composition comprising the hyperpolarized compound according to any one of aspects 1 to 14 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0270] (31) A pharmaceutical composition comprising the hyperpolarized compound according to any one of aspects 15 to 29 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0271] (32) Use of the pharmaceutical composition according to aspect 30 or aspect 31 in a method for diagnosing or monitoring a patient suffering from or suspected of suffering from cancer, the method comprising: 13 C-MRI to diagnose or monitor patients.

[0272] (33) Use of a pharmaceutical composition according to aspect 32, wherein the method comprises identifying one or more mutations that cause cancer.

[0273] (34) Use of a pharmaceutical composition according to aspect 33, wherein the method identifies an IDH1 mutation.

[0274] (35) A method for preparing the compound of aspect 1 or a pharmaceutically acceptable salt thereof, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising:

[0275] (i) reacting the compound of formula (II) with deuterium oxide in an organic solvent under alkaline conditions to obtain a compound of formula (III):

[0276]

[0277] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, and wherein Bn is benzyl; and

[0278] (ii) reacting the compound of formula (III) with DC1 and D2O or HCl and H2O to obtain the compound of aspect 1.

[0279] (36) A method for preparing the isotopic mixture of aspect 15, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising:

[0280] (i) reacting a compound of formula (II) with a deuterium oxide in an organic solvent under alkaline conditions to obtain an isotopic mixture of a compound of formula (III):

[0281]

[0282] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein Xa+

[0283] At least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xb+Xc+Xd is deuterium; and

[0284] (ii) reacting an isotopic mixture of a compound of formula (III) with DC1 and D2O or HCl and H2O to obtain the isotopic mixture of aspect 15.

[0285] (37) A method for preparing a hyperpolarized ketoglutarate compound, comprising:

[0286] (i)SABRE polarization transfer precatalyst;

[0287] (ii) combining a SABRE polarization transfer precatalyst with a ketoglutarate compound, parahydrogen, and an optional co-ligand in a solvent to form a mixture comprising an active SABRE catalyst; and

[0288] (iii) hyperpolarizing the mixture comprising the active SABRE catalyst by exposing the mixture to a magnetic field or radio frequency excitation to transfer polarization from the parahydrogen to the ketoglutarate compound to form a hyperpolarized ketoglutarate compound.

[0289] (38) The method according to aspect 37, wherein the ketoglutarate compound is a compound according to any one of aspects 1 to 14 or a pharmaceutically acceptable salt thereof, or a composition according to any one of aspects 15 to 32.

[0290] (39) The method according to aspect 38, wherein each R1 is independently a cation or a C1-C6 alkyl group.

[0291] (40) The method according to any one of aspects 37 to 39, wherein the hyperpolarized ketoglutarate compound has the formula (HP-I):

[0292]

[0293] The arrow in the formula (HP-I) represents hyperpolarization,

[0294] wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and

[0295] wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium,

[0296] or a pharmaceutically acceptable salt thereof.

[0297] (41) The method according to aspect 37, wherein the ketoglutarate compound has formula (IV):

[0298]

[0299] and wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl and a (aryl)C1-C6 alkyl,

[0300] or a pharmaceutically acceptable salt thereof.

[0301] (42) The method according to aspect 37 or 41, wherein the hyperpolarized ketoglutarate compound has the formula (HP-IV):

[0302]

[0303] The arrow in the formula (HP-IV) represents hyperpolarization,

[0304] and wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl and a (aryl)C1-C6 alkyl,

[0305] or a pharmaceutically acceptable salt thereof.

[0306] (43) The method according to any one of aspects 37-42, wherein the SABRE polarization transfer precatalyst comprises a d-block element and one or more ligands.

[0307] (44) The method according to aspect 43, wherein the one or more ligands are selected from phosphine ligands, carbene ligands, imidazole ligands, pincer chelating ligands and combinations thereof.

[0308] (45) The method according to any one of aspects 37-44, wherein the active SABRE catalyst comprises a co-ligand.

[0309] (46) The method according to aspect 45, wherein the co-ligand is a compound containing a sulfoxide group.

[0310] (47) The method according to aspect 46, wherein the compound containing a sulfoxide group is selected from DMSO, phenylmethyl sulfoxide, chloromethylphenyl sulfoxide, diphenyl sulfoxide, dibenzoyl sulfoxide and dibutyl sulfoxide.

[0311] The following examples further illustrate the invention but, of course, should not be construed as limiting its scope in any way.

[0312] Example 1

[0313] This example illustrates the preparation of 1- 13 C-3-D2-4-D-5- 12 C-Ketoglutarate method:

[0314]

[0315] In a 20mL vial, compound 1 (1.3 grams, 4.2 mmol) was dissolved in THF / D2O / Et3N (6mL:3mL:1mL). The vial was sealed and heated at 65°C overnight (14h). The reaction was cooled to room temperature and transferred to a 125mL separatory funnel and 10mL D2O was added. It was treated with CH2Cl2 (2*50mL), dried over anhydrous Na2SO4, and the filtrate was concentrated under reduced pressure to give compound 2 (1.2 grams, 92% yield, 95% D at C-3, 50% D at C-4). 1 H NMR (400MHz, CdCl3) δ7.45–7.28(m,5H),5.11(s,2H),3.85–3.36(m,6H),2.79–2.71(m,1H).

[0316]

[0317] Compound 2 (1.53 g, 5 mmol) was added to a 3 molar solution of DCl in D2O (50 mL). The reaction mixture was stirred at 80 °C for 16 h under an argon atmosphere. The solvent was removed in vacuo to obtain a syrup. The crude product was purified by ion chromatography on formic acid resin (15 g, Bio-Rad AG 1-X8, 100-200 mesh). The column was adjusted with 4M HCOOH and washed with D2O until a pH of 6.5 was observed. The crude product was dissolved in D2O (10 mL) and loaded onto the column. The column was eluted with D2O (200 mL) and then with 3M DCl (200 mL) in D2O. The DCl phase was concentrated in vacuo and freeze-dried from D2O. A yellow solid was obtained, which was crystallized from a minimum amount of EtOAc at -20 °C to produce 3 (0.57 g, 75% yield). Any contact of compound 3 with water results in deuterium-hydrogen exchange of the carboxylic acid protons (ie, R1) and, in some cases, at carbon positions 3 and 4. The deuterated compounds were characterized by qualitative NMR using maleic acid as an internal standard. 13 C NMR (101MHz, Cd3CN) δ169.13, 160.81. 1 H NMR:

[0318]

[0319] Example 2

[0320] This example illustrates the synthesis of 2-oxo-5- 12 C-1- 13 C sodium glutarate method.

[0321]

[0322] 2-Oxo-5- 12 C-1- 13 C glutaric acid (16 mg, 0.11 mmol) was dissolved in 200 μL of deuterium oxide and 40% sodium deuterium oxide in water (20 μL, 0.22 mmol) was added. The solution was lyophilized to give the desired product and used further directly.

[0323] Example 3

[0324] This example illustrates a method for synthesizing a SABRE catalyst according to one aspect of the present invention.

[0325] In a glove box, a solution of 1,3-bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene (1 g, 3 mmol, Aldrich) in 20 mL THF was added dropwise (over 15 min) to a stirred solution of [{Ir(μ-Cl)(COD)}2] (1 g, 1 mmol, Aldrich) in 3 mL THF.

[0326] The solution was stirred for 12 h, then removed from the glove box and concentrated to about ~20% of the remaining solution volume. Dry and deoxygenated pentane was added to precipitate the complex. The yellow precipitate was filtered and recrystallized (1.07 g, 99% yield).

[0327] Ultra-high purity hydrogen (Airgas) was delivered to a parahydrogen (pH2) stream cryostat (Xeus technology LTD) and enriched to about 50% parahydrogen in the presence of a spin exchange catalyst (Fe2O3) at liquid nitrogen temperature (77K). The pH2 stream was directed to a mass flow controller (MFC, Sierra Instruments SmartTrak 100 series) set to 90 ssc / m via PTFE tubing and to a conventional 5 mm NMR tube (Norell) to allow bubbling through the sample. The entire pH2 line was pressurized to 96 psi.

[0328] Magnetic fields close to or below 1 μT were obtained using a homemade device consisting of a solenoid coil placed inside a mu-metal shield (Magnetic Shield Corporation, Model ZG-206). At least once a day, the shield was degaussed using an internal coil driven by a variac (Variac). The solenoid had a 41 mm diameter (40 mm core), a 20 cm long winding with 220 turns of AWG20 (0.9 mm) Cu wire, and a 220 Ω series resistor. The solenoid coil was driven by a commercial 1.5 V battery with a series variable resistor decade box to provide finer control of the internal magnetic field inside the shield. Conventional values ​​of the field inside the shield were between ±1.2 μT, while SABRE SHEATH experiments were typically between 0.5 μT and 0.8 μT in the sample area. These values ​​were monitored between SABRE experiments using a Lakeshore Cryotronics Gaussmeter (Model 475DSP) with a HMMA-2512-VR Hall probe.

[0329] NMR experiments were performed using a 1T Magritek Spinsolve benchtop NMR spectrometer. 13 C NMR spectra are all closed 1The time required to manually transfer the sample from the shielded area to the magnet for low-field NMR acquisition is typically <5 s.

[0330] From p-H2 derived hydride to [1- 13 C]ketoglutarate 13 Efficient hyperpolarization transfer of C nuclear spins is possible by using [IrCl(H)2(DMSO)2(IMes)], [1- 13 C]ketoglutarate) and p-H2 in deuterated methanol using SABRE in SHield Enables Alignment Transfer to Heteronuclei (SABRE-SHEATH) implemented in a sub-microtesla magnetic field.

[0331]

[0332] All experiments were performed with a mixture containing 7.8 mM precatalyst, 45 mM DMSO and 10 mM [1- 13 The experiments were conducted at room temperature, ~100 sccm p-H2 flow rate and 96 PSI p-H2 overpressure. The parahydrogen used in this example came from a low-cost 50% p-H2 generator.

[0333] For each experiment, pH 2 bubbling was applied for ~1 min, the sample was quickly transferred to a 1.4T NMR spectrometer for detection, and then the sample was placed back into the mu-metal shield to continue pH 2 bubbling for the next experiment.

[0334] A schematic diagram of the SABRE-SHEATH hyperpolarized catalytic system is shown below. 2 -[1- 13 C]ketoglutarate)(DMSO)(IMes)], transferring magnetization from p-H2 to [1- 13 C] Ketoglutarate. Both p-H2 and ketoglutarate have weak, transient binding to the iridium complex.

[0335]

[0336] The results obtained from the SABRE-SHEATH experiment are Figure 2 The top scan shows a single scan HP selected from the SABRE-SHEATH experiment with an enhancement of ε ∼ 3,000 13 C spectrum and polarization is about P(13 C) ~0.24%. Sample: 10 mM [1- 13 C] sodium ketoglutarate, 45 mM DMSO, 7.8 mM Ir-IMes catalyst in methanol-d4; T = After pH 2 bubbling at -0.2 μT for 55 s, the sample was manually transferred to 1 T and the spectra were immediately acquired.

[0337] Figure 2 The bottom scan in the figure shows a 4M[1- 13 Single-scan thermal polarization of sodium acetate 13 C signal.

[0338] Example 4

[0339] This embodiment provides a hyperpolarized [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C SABRE-SHEATH hyperpolarization results, prepared as in Example 1, using SABRE catalyst, such as Figure 3A shown.

[0340] Prepare CD3OD containing 5 mM [1- 13 C,5- 12 C; d4]α-ketoglutarate, 20mM DMSO, 5mM Figure 3A The sample composition of the catalyst and 0.5M water shown in . The sample was loaded into a medium wall thickness NMR tube and argon was bubbled through the sample for 60 seconds to remove trapped air. Next, the sample was activated by bubbling parahydrogen (p-H2) for about 5 minutes or more at a flow rate of 70 standard cubic centimeters (sccm) per minute and 100PSI p-H2 overpressure (total p-H2 pressure ~8atm) in a SABRE-SHEATH apparatus as shown in Example 3. For each experimental run, p-H2 was bubbled through the sample for 60 seconds and transferred to a 1.4T benchtop SpinSolve NMR spectrometer for detection. The results are shown in Figure 3B-3H Unless otherwise stated, all experiments were performed at T T = +10°C using a SpinSolve NMR spectrometer at 1.4T in CD3OD.

[0341] Figure 3B Provides hyperpolarization [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C NMR spectroscopy. Figure 3C Provides 5mM [1- 13 C,5-12 C; d4] Temperature variation of representative stacking of α-ketoglutarate 13 C NMR spectroscopy, which demonstrated Figure 3A Interaction between the hyperpolarized complex 3b in and the 'free' peak during SABRE-SHEATH hyperpolarization as a function of temperature. Figure 3D Provides thermally polarized pure [1- 13 C]Acetic acid 13 C NMR spectrum, which was used as a signal reference for calculating signal enhancement. Figure 3E Provided in B T =0.42μT [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13 Superposition and attenuation of the C polarization (ie, integrating over all bound and free resonances). Figure 3F The corresponding magnetic fields of the benchtop spectrometer in the earth's magnetic field and the clinically relevant 1.4T magnetic field are provided. 13 C-1T1 relaxation curve. Figure 3G Provides [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13 C polarization as a function of temperature. Figure 3H Provides [1- 13 C,5- 12 C;d4]α-ketoglutarate 13 C-1 Total 13 C polarization as a function of the magnetic transfer field.

[0342] In addition, the spin-lattice relaxation time was measured and found to be as follows: in a 3T MR solution MRI system in a solution of DPBS and EDTA, T1 (flip angle corrected [1- 13 C,5- 12 C; d4]α-ketoglutarate) = 97.1 ± 0.416 seconds (apparent T1 = 39.1 ± 0.414 seconds). 13 C,5- 12 C; d4] α-ketoglutarate, measured spin-lattice relaxation time, and found the following: in the 3T MR solution MRI system in DPBS and EDTA solution, T1 (flip angle corrected as prepared in Example 2 [1- 13 C,5- 12 C] protonated α-ketoglutarate) = 63.0 ± 0.835 seconds (apparent T1 = 32.1 ± 0.824 seconds).

[0343] Example 5

[0344] This example provides a method for hyperpolarizing naturally abundant disodium α-ketoglutarate 13 C SABRE-SHEATH hyperpolarization results, using SABRE catalysts such as Figure 4A as shown in .

[0345] Prepare a solution containing 5.6 mM naturally abundant α-ketoglutarate disodium, 20 mM DMSO, 5 mM Figure 4A The sample composition of the catalyst and 0.5M water as shown. The sample was loaded into a medium wall thickness NMR tube and argon was bubbled through the sample for 60 seconds to remove trapped air. Next, the sample was activated by bubbling parahydrogen (p-H2) for about 5 minutes or more at a flow rate of 70 standard cubic centimeters (sccm) per minute and 100PSI p-H2 overpressure (total p-H2 pressure ~8atm) in a SABRE-SHEATH apparatus as shown in Example 3. For each experimental run, p-H2 was bubbled through the sample for 60 seconds and transferred to a 1.4T benchtop SpinSolve NMR spectrometer for detection. The results are shown in Figure 4B-Figure 4G Unless otherwise stated, all experiments were performed at T T = +10°C using a SpinSolve NMR spectrometer at 1.4T in CD3OD.

[0346] Figure 4B Provided is a representative sample of a 5.6 mM solution of naturally abundant disodium α-ketoglutarate obtained by SABRE-SHEATH in CD3OD at +10 °C 13 C NMR spectroscopy. Figure 4C Provides thermally polarized pure [1- 13 C]Acetic acid 13 CNMR spectra, which were used as signal references for calculating signal enhancement. Figure 4D Provided in B T =0.42μT and T T = Total in disodium α-ketoglutarate at +10°C 13 Superposition and attenuation of the C polarization (ie, integrating over all bound and free resonances). Figure 4E The total (bound + free) concentrations of α-ketoglutarate disodium in the Earth's magnetic field and in a clinically relevant benchtop spectrometer at 1.4 T are provided. 13 C polarization attenuation. Figure 4F Provides natural abundance of alpha-ketoglutarate disodium 13 C-1 Total 13 C polarization as a function of temperature. Figure 4G Provides natural abundance of alpha-ketoglutarate disodium 13C-1 Total 13 C polarization as a function of the magnetic transfer field.

[0347] The results of Examples 4 and 5 show that: (i) at position 1 of α-ketoglutarate 13 C labeling enables spectroscopic detection, (ii) deuteration at positions 3 and 4 enables the 13 The lifetime of the C-1 hyperpolarized state is maximized, and (iii) the 12 The C labeling minimizes the background signal from this resonance.

[0348] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0349] Unless otherwise specified herein or clearly contradictory to the context, the use of the terms "a", "an", "the" and similar indicators in the context of describing the present invention (particularly in the following claims) should be interpreted as covering the singular and the plural. Unless otherwise specified herein or clearly contradictory to the context, a series of one or more items (e.g., "at least one (kind) of A and B") after the term "at least one (a)" should be interpreted as meaning an item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B). Unless otherwise specified, the terms "comprising", "having", "including" and "containing" should be interpreted as open terms (i.e., meaning "including but not limited to"). Unless otherwise specified herein, the description of the numerical range herein is intended only to be used as a shorthand method of individually referring to each individual numerical value falling within the range, and each individual numerical value is incorporated into the specification as if it were individually described herein. Unless otherwise specified herein or clearly contradictory to the context, all methods described herein can be performed in any suitable order. Unless otherwise stated, the use of any and all examples or exemplary language (e.g., "for example") provided herein is intended only to better illustrate the present invention and is not intended to limit the scope of the present invention. No language in this specification should be construed as indicating that any unclaimed element is essential to the implementation of the present invention.

[0350] Preferred embodiments of the present invention are described herein, including the best mode for implementing the present invention by the inventor. Variations of those preferred embodiments will be clear to those of ordinary skill in the art after reading the above description. The inventor expects that such variations will be appropriately applied by skilled artisans, and the inventor intends to implement the present invention in a manner different from that specifically described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter described in the appended claims as permitted by applicable law. In addition, unless otherwise noted herein or clearly contradictory in context, any combination of all possible variations of the above elements is also included in the present invention.

Claims

1. Compound of formula (I): wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein one of Xa and Xb is deuterium and the other is hydrogen, and both Xc and Xd are hydrogen, as shown in formula (Ia): or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein one of Xc and Xd is deuterium and the other is hydrogen, and both Xa and Xb are hydrogen, as shown in formula (Ib): or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1, wherein one of Xa and Xb is deuterium and the other is hydrogen, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (Ic): or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein both Xa and Xb are deuterium and both Xc and Xd are hydrogen, as shown in formula (Id): or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein both Xa and Xb are hydrogen and both Xc and Xd are deuterium, as shown in formula (Ie): or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1, wherein both Xa and Xb are deuterium, and one of Xc and Xd is deuterium and the other is hydrogen, as shown in formula (If): or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1, wherein both Xc and Xd are deuterium, and one of Xa and Xb is deuterium and the other is hydrogen, as shown in formula (Ig): or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1, wherein Xa, Xb, Xc and Xd are deuterium, as shown in formula (Ih): or a pharmaceutically acceptable salt thereof.

10. A compound according to any one of claims 1 to 9, wherein each R1 is independently selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C1-C6 alkyl, (heterocycloalkyl)C1-C6 alkyl, (heteroaryl)C1-C6 alkyl and (aryl)C1-C6 alkyl.

11. The compound according to any one of claims 1-9, wherein each R1 is independently selected from C1-C6 alkyl.

12. A compound according to any one of claims 1-9, wherein each R1 is hydrogen.

13. The compound of any one of claims 1-9, wherein each R1 is deuterium.

14. A compound according to any one of claims 1-9, wherein each R1 is a cation.

15. A composition comprising an isotopic mixture of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein at least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

16. The composition of claim 15, wherein at least 50% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

17. The composition of claim 15, wherein at least 75% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

18. The composition of claim 15, wherein at least 95% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium.

19. The composition of any one of claims 15-18, wherein at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

20. The composition of any one of claims 15-18, wherein at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

21. The composition of any one of claims 15-18, wherein at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xa+Xb is deuterium.

22. The composition of any one of claims 15-21, wherein at least 50% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

23. The composition of any one of claims 15-21, wherein at least 75% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

24. The composition of any one of claims 15-21, wherein at least 95% of the sum of deuterium atoms and hydrogen atoms defined by Xc+Xd is deuterium.

25. A composition according to any one of claims 15-24, wherein each R1 is independently selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C1-C6 alkyl, (heterocycloalkyl)C1-C6 alkyl, (heteroaryl)C1-C6 alkyl and (aryl)C1-C6 alkyl.

26. The composition of any one of claims 15-24, wherein each R1 is independently a C1-C6 alkyl.

27. A composition according to any one of claims 15-24, wherein each R1 is hydrogen.

28. The composition of any one of claims 15-24, wherein each R1 is deuterium.

29. A composition according to any one of claims 15-24, wherein each R1 is a cation.

30. A pharmaceutical composition comprising the hyperpolarized compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising the hyperpolarized composition of any one of claims 15 to 29 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

32. A pharmaceutical composition according to claim 30 or claim 31 for use in a method of diagnosing or monitoring a patient suffering from or suspected of suffering from cancer, the method comprising: 13 C-MRI to diagnose or monitor the patient.

33. A pharmaceutical composition for use according to claim 32, wherein the method comprises identifying one or more mutations that cause the cancer.

34. The pharmaceutical composition for use according to claim 33, wherein the method identifies IDH1 mutations.

35. A method for preparing the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising: (i) reacting a compound of formula (II) with deuterium oxide in an organic solvent under alkaline conditions to obtain a compound of formula (III): wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, and wherein Bn is benzyl; and (ii) reacting the compound of formula (III) with DC1 and D2O or HCl and H2O to obtain the compound of claim 1.

36. A method for preparing the isotopic mixture of claim 15, wherein each R1 is independently selected from hydrogen, deuterium and a cation, the method comprising: (i) reacting a compound of formula (II) with a deuterium oxide in an organic solvent under alkaline conditions to obtain an isotopic mixture of a compound of formula (III): wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, and wherein at least 25% of the sum of the deuterium atoms and hydrogen atoms defined by Xa+Xb+Xc+Xd is deuterium; and (ii) reacting the isotopic mixture of the compound of formula (III) with DC1 and D2O or HCl and H2O to obtain the isotopic mixture of claim 15.

37. A method for preparing a hyperpolarized ketoglutarate compound, comprising: (i) providing a SABRE polarization transfer precatalyst; (ii) mixing the SABRE polarization transfer precatalyst with a ketoglutarate compound, secondary hydrogen, and an optional co-ligand in a solvent to form a mixture comprising an active SABRE catalyst; as well as (iii) hyperpolarizing the mixture by exposing the mixture comprising the active SABRE catalyst to a magnetic field or radio frequency excitation to transfer the polarization from the parahydrogen to the ketoglutarate compound to form the hyperpolarized ketoglutarate compound.

38. The method of claim 37, wherein the ketoglutarate compound is a compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1-14 or a composition as described in any one of claims 15-32.

39. The method of claim 38, wherein each R1 is independently a cation or a C1-C6 alkyl group.

40. The method of any one of claims 37-39, wherein the hyperpolarized ketoglutarate compound has the formula (HP-I): wherein the arrow in formula (HP-I) represents the hyperpolarization, wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl, and a (aryl)C1-C6 alkyl; and wherein Xa, Xb, Xc and Xd are each independently hydrogen or deuterium, provided that at least one of Xa, Xb, Xc and Xd is deuterium, or a pharmaceutically acceptable salt thereof.

41. The method of claim 37, wherein the ketoglutarate compound has formula (IV): and wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl and a (aryl)C1-C6 alkyl, or a pharmaceutically acceptable salt thereof.

42. The method of claim 37 or 41, wherein the hyperpolarized ketoglutarate compound has the formula (HP-IV): wherein the arrow in formula (HP-IV) represents the hyperpolarization, and wherein each R1 is independently selected from hydrogen, deuterium, a cation, a C1-C6 alkyl, a C3-C7 cycloalkyl, a (C3-C7 cycloalkyl)C1-C6 alkyl, a (heterocycloalkyl)C1-C6 alkyl, a (heteroaryl)C1-C6 alkyl and a (aryl)C1-C6 alkyl, or a pharmaceutically acceptable salt thereof.

43. The method of any one of claims 37-42, wherein the SABRE polarization transfer precatalyst comprises a d-block element and one or more ligands.

44. The method of claim 43, wherein the one or more ligands are selected from the group consisting of phosphine ligands, carbene ligands, imidazole ligands, pincer chelating ligands, and combinations thereof.

45. The method of any one of claims 37-44, wherein the active SABRE catalyst comprises a co-ligand.

46. ​​The method of claim 45, wherein the co-ligand is a compound comprising a sulfoxide group.

47. The method of claim 46, wherein the compound comprising a sulfoxide group is selected from DMSO, phenylmethyl sulfoxide, chloromethylphenyl sulfoxide, diphenyl sulfoxide, dibenzoyl sulfoxide, and dibutyl sulfoxide.